Fmr LLC Has $10,978,000 Stake in Vermillion, Inc. (VRML)

FMR LLC held its position in shares of Vermillion, Inc. (NASDAQ:VRML) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,252,463 shares of the company’s stock at the end of the first quarter. FMR LLC owned about 9.36% of Vermillion worth $10,978,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in VRML. M&T Bank Corp raised its stake in shares of Vermillion by 48.2% in the first quarter. M&T Bank Corp now owns 230,500 shares of the company’s stock worth $482,000 after buying an additional 75,000 shares in the last quarter. Greenwich Wealth Management LLC acquired a new stake in shares of Vermillion during the first quarter worth about $276,000. Finally, Birchview Capital LP increased its stake in shares of Vermillion by 1.3% in the first quarter. Birchview Capital LP now owns 2,752,933 shares of the company’s stock worth $5,649,000 after buying an additional 35,419 shares during the last quarter. Institutional investors own 35.66% of the company’s stock.

Shares of Vermillion, Inc. (VRML) traded down 5.51% on Friday, reaching $1.20. 47,895 shares of the company traded hands. Vermillion, Inc. has a 1-year low of $0.76 and a 1-year high of $2.85. The company has a 50-day moving average of $1.57 and a 200-day moving average of $1.81. The stock’s market capitalization is $67.40 million.

Vermillion (NASDAQ:VRML) last issued its earnings results on Wednesday, August 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Vermillion had a negative net margin of 370.69% and a negative return on equity of 215.53%. The firm had revenue of $0.90 million during the quarter. Analysts anticipate that Vermillion, Inc. will post ($0.16) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at

Separately, ValuEngine raised shares of Vermillion from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd.

About Vermillion

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Institutional Ownership by Quarter for Vermillion (NASDAQ:VRML)

What are top analysts saying about Vermillion Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vermillion Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit